Rare Neurological Disease Treatment

8.5% Global CAGR for Rare Neurological Disease Treatment Market Market to achieve US$ 13,830.96 Mn by 2027

Johnson & Johnson Services, Inc, Novartis AG. – Notable Market Players in Rare Neurological Disease Treatment Market

Neurological diseases having less diagnostics and treatment options affecting small number of population is termed as rare neurological diseases. These diseases target the nervous system, which include the brain, spinal cord, and all the nerves that run throughout the human body. Amyotrophic lateral sclerosis (ALS), Duchenne muscular dystrophy, Huntington’s disease are few examples of rare neurological conditions.

Market leaders operating in the market have undertaken various organic growth strategies in the rare neurological disease treatment market. The rare neurological disease treatment market majorly consists of the players such as Allergan plc, Bayer AG, GlaxoSmithKline plc, Johnson & Johnson Services, Inc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd and Takeda Pharmaceutical Company Limited among others. Several organic approaches, such as product launches, and expansion/relocation in the rare neurological disease treatment market, have resulted in the positive growth of the market. Product launches help the company to strengthen its product offering and the customer base, which allows the company to hold a strong position in the market. Similarly, utilizing expansion activities, it is easy to venture into untapped economies and use the opportunities being offered.

Below is the list of the growth strategies done by the players operating in the Rare Neurological Disease Treatment market:

Year

News

Feb-20

Followed by U.S. Food and Drug Administration (FDA) approval for UBRELVY (ubrogepant), Allergan plc launched the product in 2020 for adults with acute migraine with or without aura

Jan-20

Charles River has entered a multi-year drug discovery collaboration with Takeda Pharmaceutical Co. to launch multiple integrated programs across Takeda’s four core therapeutic areas—oncology, gastroenterology, neuroscience, and rare disease—with the goal of delivering preclinical candidates that Takeda can advance into clinical development.

Nov-19

Merck (MSD) has acquired small molecule therapies developer Calporta Therapeutics. The company develops small molecule agonists to treat lysosomal storage diseases and neurodegenerative disorders.

Dec-19

Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, has formed a multi-year research alliance with Takeda Pharmaceutical Company Limited (“Takeda”) to identify novel target proteins expressed in the central nervous system and to develop new therapies

Apr-19

Teva won EC Marketing Authorization for its Ajovy pre-filled syringe injection meant to serve as a prophylaxis for migraines in adults who experience at least four migraine days per month.

 

 

Leave a Reply

Your email address will not be published. Required fields are marked *